title: Importance of Geriatric Syndromes in Older Patients with Diabetes with de novo Insulin Treatment: The VEGAS Study.
abstract: OBJECTIVE
  The VEGAS study was conducted to evaluate representative data of de novo insulin-treated older patients with type 2 diabetes in the outpatient setting in Germany.
  
  
  METHODS
  In this prospective, multicenter, non-interventional observational study, a nationwide written survey was carried out among practitioners (02/2011-06/2011). Older patients, aged ≥70 years, starting de novo insulin therapy, were documented.
  
  
  RESULTS
  Data from 4,858 patients from about 500 centers (mean age: 78.2 ± 5.4 years; mean glycosylated hemoglobin [HbA1c]: 70 ± 14.2 mmol/mol [8.6 ± 1.3 %]) were collected. The mean target HbA1cvalue was 55 ± 6.6 mmol/mol (7.2 ± 0.6 %). 91.1 % of geriatric patients were multi-morbid. 96.2 % showed at least one physical or psychological geriatric syndrome. Most of the patients were notably impaired according to their age. Conventional insulin therapy and basal-supported oral therapy were the most frequently planned treatment regimens (39.1 and 31.1 %). Important factors in the selection of the insulin treatment regimen were an efficient HbA1cdecrease (65.6 %), easy administration (55.7 %), and also a patient's ability to self-administer insulin (38.5 %). De novo insulin treatment increased care requirements (22.7 %). 22.3 % of the relatives were scheduled to receive special training. Specific training programs for older patients with diabetes were planned in only 7.3 % of cases.
  
  
  CONCLUSIONS
  The data demonstrate the high prevalence of geriatric syndromes during de novo insulin treatment. Individual therapeutic goals and regimes are based on practicability, in particular, the receipt of autonomy and the care requirement. Diabetes education with adapted programs is currently under-represented. Important factors for the choice of an insulin treatment regimen were an efficient HbA1cdecrease, easy administration, and a patient's ability for self-administration.
authors.affiliation: University of Ulm, Institute of Epidemiology, Albert-Einstein-Allee 41, 89081, Ulm, Germany. andrej.zeyfang@bethesda-stuttgart.de.|AGAPLESION Bethesda Hospital Stuttgart, Hohenheimer Strasse 21, 70184, Stuttgart, Germany. andrej.zeyfang@bethesda-stuttgart.de.
authors.forename: Andrej
authors.initials: A
authors.lastname: Zeyfang
authors.affiliation: BERLIN-CHEMIE AG, Berlin, Germany.
authors.forename: Andrea
authors.initials: A
authors.lastname: Patzelt-Bath